Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kalff

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
American Journal of Hematology|May 30, 2012
Lenalidomide in multiple myeloma: Current status and future potentialHang Quach, Anna Kalff, Andrew Spencer
British Journal of Haematology|March 30, 2010
The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adultsAnna Kalff, Claire Dowsing, Andrew Grigg
Cancer Biology & Medicine|July 27, 2016
Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignanciesJay Hocking, Sridurga Mithraprabhu, Anna Kalff, et al.
Epigenetics|December 9, 2014
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myelomaSridurga Mithraprabhu, Anna Kalff, Annie Chow, et al.
Frontiers in Oncology|June 6, 2022
The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma PracticeRose Turner, Anna Kalff, Krystal Bergin, et al.
Heart & Lung : the Journal of Critical Care|May 22, 2018
Idiopathic systemic capillary leak syndrome presenting as septic shock: A case reportEamon P Raith, Joshua F Ihle, Jennifer Jamieson, et al.
British Journal of Haematology|May 15, 2021
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trialKrystal Bergin, Flora Yuen, Craig Wallington-Beddoe, et al.
Internal Medicine Journal|July 9, 2022
Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experiencePhillip C Nguyen, Jenny Muirhead, Joanne Tan, et al.
Bone Marrow Transplantation|December 2, 2020
Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myelomaJoanne L C Tan, Tongted Das, David Kliman, et al.
British Journal of Haematology|May 31, 2013
Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chainsDenise Lee, Anna Kalff, Michael Low, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
American Journal of Hematology|May 30, 2012
Lenalidomide in multiple myeloma: Current status and future potentialHang Quach, Anna Kalff, Andrew Spencer
British Journal of Haematology|March 30, 2010
The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adultsAnna Kalff, Claire Dowsing, Andrew Grigg
Cancer Biology & Medicine|July 27, 2016
Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignanciesJay Hocking, Sridurga Mithraprabhu, Anna Kalff, et al.
Epigenetics|December 9, 2014
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myelomaSridurga Mithraprabhu, Anna Kalff, Annie Chow, et al.
Frontiers in Oncology|June 6, 2022
The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma PracticeRose Turner, Anna Kalff, Krystal Bergin, et al.
Heart & Lung : the Journal of Critical Care|May 22, 2018
Idiopathic systemic capillary leak syndrome presenting as septic shock: A case reportEamon P Raith, Joshua F Ihle, Jennifer Jamieson, et al.
British Journal of Haematology|May 15, 2021
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trialKrystal Bergin, Flora Yuen, Craig Wallington-Beddoe, et al.
Internal Medicine Journal|July 9, 2022
Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experiencePhillip C Nguyen, Jenny Muirhead, Joanne Tan, et al.
Bone Marrow Transplantation|December 2, 2020
Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myelomaJoanne L C Tan, Tongted Das, David Kliman, et al.
British Journal of Haematology|May 31, 2013
Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chainsDenise Lee, Anna Kalff, Michael Low, et al.
Pageof 3